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Abstract
In recent studies, the amyloid form of recombinant prion protein (PrP) encompassing residues 89–230 (rPrP
89-230) produced in vitro induced transmissible prion disease in mice. These studies showed that unlike
“classical” PrPSc produced in vivo, the amyloid fibrils generated in vitro were more proteinase-K sensitive.
Here we demonstrate that the amyloid form contains a proteinase K-resistant core composed only of residues
152/153–230 and 162–230. The PK-resistant fragments of the amyloid form are similar to those observed
upon PK digestion of a minor subpopulation of PrPSc recently identified in patients with sporadic
Creutzfeldt-Jakob disease (CJD). Remarkably, this core is sufficient for self-propagating activity in vitro and
preserves a -sheet-rich fibrillar structure. Full-length recombinant PrP 23-230, however, generates two
subpopulations of amyloid in vitro: One is similar to the minor subpopulation of PrPSc, and the other to
classical PrPSc. Since no cellular factors or templates were used for generation of the amyloid fibrils in vitro,
we speculate that formation of the subpopulation of PrPSc with a short PK-resistant C-terminal region
reflects an intrinsic property of PrP rather than the influence of cellular environments and/or cofactors. Our
work significantly increases our understanding of the biochemical nature of prion infectious agents and
provides a fundamental insight into the mechanisms of prions biogenesis.
Keywords: prion protein; amyloid fibrils; conformational transition; proteinase K; Creutzfeldt-Jakob
disease
Several severe neurodegenerative diseases including
Creutzfeldt-Jakob disease (CJD), Gerstmann-Straussler-
Sheinker disease, and fatal familial insomnia are associated
with misfolding and aggregation of the prion protein
(Prusiner 2001). Prion maladies manifest themselves in in-
fectious, familial, and sporadic forms. To explain the infec-
tious form of the prion diseases, the “protein-only hypoth-
esis” postulates that an abnormal isoform of the prion pro-
tein, PrPSc, acts as an infectious agent and propagates its
pathological conformation in an autocatalytic manner using
the normal isoform of the same protein, PrPC, as a substrate
(Prusiner 1982).
PrPC and PrPSc differ substantially in their conforma-
tions. Unlike PrPC, PrPSc is a multimeric assembly charac-
terized by enhanced resistance to proteinase K (PK) diges-
tion and by an increase in the amount of -sheet structure
Reprint requests to: Ilia V. Baskakov, 725 W. Lombard Street, Balti-
more, MD 21201, USA; e-mail: Baskakov@umbi.umd.edu; fax: (410)
706-8184.
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(Caughey et al. 1991; Pan et al. 1993). The detailed three-
dimensional structure of the PrPC isoform has been deter-
mined (Riek et al. 1996, 1997; Donne et al. 1997; Haire et
al. 2004), whereas structural information about PrPSc is
more limited due to its insolubility, heterogeneity, and
highly aggregated state (Gabizon and Prusiner 1990; Wille
et al. 2002).
In contrast to PrPC, PrPSc exists in multiple conforma-
tions, which are believed to result from infection of animals
with different strains of TSE (transmissible spongiform en-
cephalopathy) agent. The existence of different prion strains
has been recognized for many years (Dickinson et al. 1968;
Fraser and Dickinson 1973), but has only recently been
linked to the conformational diversity of PrPSc. According
to the template-assisted model, each conformation of PrPSc
can act as a unique template, providing conformational con-
straints for the formation of nascent PrPSc and, therefore,
determining the conformation of nascent PrPSc (Cohen et al.
1994). Biochemical assays have been described that distin-
guish conformers of PrPSc by the extent of PK resistance,
the size of the PK-resistant core, thermodynamic stability,
epitope presentation, and relative amount of -sheet-rich
structure (Bessen and Marsh 1994; Telling et al. 1996;
Caughey et al. 1998; Safar et al. 1998; Peretz et al. 2001).
Conformationally different subtypes of PrPSc have also
been found in patients with sporadic CJD (spCJD) (Parchi et
al. 1999; Hill et al. 2003). These PrPSc subtypes have varia-
tions in the molecular mass of the PK-resistant core and
exhibit different ratios of di-, mono-, and unglycosylated
PrPSc. Conformational diversity of PrPSc subtypes is linked
to the methionine/valine polymorphism at codon 129 and
may also be affected by unidentified host factors (Telling et
al. 1995; Parchi et al. 2000).
To distinguish different conformers and to classify sub-
types of PrPSc, limited digestion with PK has been used
widely since it offers a rapid and accurate assay of altered
PrPSc conformation (McKinley et al. 1983; Bessen and
Marsh 1994; Safar et al. 1998; Parchi et al. 1999; Hill et al.
2003). Normally, treatment of PrPSc with PK generates a
C-terminal PK-resistant core, referred to as PrP 27-30
(McKinley et al. 1983; Oesch et al. 1985). Depending on the
subtype of PrPSc, PrP 27-30 exhibits minor variations in gel
mobility due to differences in the PK cleavage site between
residues 79 and 103 (Parchi et al. 2000). In addition, two
novel PK-resistant fragments were identified recently in pa-
tients with spCJD (Zou et al. 2003). Deglycosylated forms
of these novel PK-resistant fragments migrate at 13 and 12
kDa by SDS-PAGE, and are generated by cleavage at resi-
dues 154/156 and 162/167, respectively, retaining the C-
terminal region intact (Zou et al. 2003). Multiple factors
including gene polymorphism, glycosylation, and as yet un-
identified cellular factors may contribute to the broad con-
formational diversity of PrPSc. It is therefore important to
know whether this conformational diversity reflects an in-
trinsic property of PrP or arises only with assistance from
other molecules in a cell. Is unglycosylated recombinant
PrP (rPrP) capable of mimicking any known PrPSc subtypes
in the absence of the cellular environment or templating?
To address this question we investigated the amyloid
form of mouse (Mo) rPrP spanning residues 89–230 (rPrP
89-230) by use of limited proteolysis with PK. In our pre-
vious studies, we showed that in vitro conversion of rPrP to
the amyloid form in the absence of the cellular environment
exhibited peculiar features of the autocatalytic process and
was limited by a species barrier, two key aspects of prion
propagation (Baskakov 2004). Furthermore, we demon-
strated that the amyloid form of Mo rPrP 89-230 generated
in vitro induces a transmissible form of prion disease in
transgenic mice expressing mouse PrP 89-230 (Baskakov et
al. 2002; Legname et al. 2004). Long incubation times ob-
served upon inoculation of the amyloid fibrils suggest that
the fibrils generated in vitro have very low infectivity titers.
However, shortening of the incubation times observed in the
subsequent passages of the synthetic prions in transgenic
and wild-type mice allows an alternative explanation. One
may speculate that the synthetic prions undergo adaptation
upon propagation in vivo, and that the differences in the
incubation time are attributed to an apparent transmission
barrier. Consistent with this hypothesis are several lines of
evidence including biochemical and neuropathological fea-
tures that indicate that the synthetic prions induced a novel
strain of prion disease in experimental animals. Encouraged
by these findings, we wished to determine whether the amy-
loid fibrils, produced in vitro without other cellular compo-
nents or PrPSc-templating, structurally resembled any
known isoforms or subtypes of PrPSc.
Here we demonstrate that that the amyloid fibrils closely
resemble the novel subpopulation of PrPSc associated with
spCJD. Using PK digestion we identified three major PK-
resistant fragments in the amyloid form. These fragments
migrated at about 12 kDa, 10 kDa, and 8 kDa by SDS-
PAGE and encompassed residues 138/141–230, 152/153–
230, and 162–230, respectively, as determined by mass
spectrometry. This suggests that the slow propagation rate
observed in the first passage and an apparent transmission
barrier are due to a proteolytically labile region encompass-
ing residues 89–138. Remarkably, upon digestion with PK,
short C-terminal fragments remained assembled in fibrillar
structures, maintained high -sheet content, and preserved
their seeding activity. Since no cellular factors and tem-
plates were used to generate the amyloid form in vitro, we
suggest that the formation of the novel subpopulation of
PrPSc with this particular PK-resistant core reflects an in-
trinsic property of PrP.
Results and Discussion
It is well established that PrPSc is highly resistant toward
denaturation and remains infectious even in extreme dena-
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turing conditions (Prusiner et al. 1993). Conversely, the
thermodynamic stability of PrPC is modest and comparable
to that of other globular proteins (Baskakov et al. 2001). To
test whether the amyloid conformation of rPrP 89-230 pos-
sesses increased thermodynamic stability, we investigated
guanidinium hydrochloride (GdnHCl)-induced denaturation
at various temperatures. The amyloid form of Mo rPrP 89-
230 was produced in vitro as described (Baskakov et al.
2002). At 24°C, C1/2 (the concentration of GdnHCl at the
midpoint of denaturation) of GdnHCl-induced denaturation
of the amyloid fibrils was 4.2 M, while increasing the tem-
perature to 57°C decreased C1/2 to 3.1 M (Fig. 1). These
results demonstrate that either high concentrations of Gd-
nHCl or increased temperatures and intermediate GdnHCl
concentrations are required for denaturation of amyloid
form. In contrast, -monomeric form of rPrP can be dena-
tured by moderate concentrations of GdnHCl (C1/2  2.2 M
at room temperature) (Swietnicki et al. 1998). Remarkably,
the C1/2 value for denaturation of amyloid fibrils generated
in vitro (4.2 M) was identical to the C1/2 value determined
for the mouse synthetic prion strain 1 (MoSP1) produced in
the brains of Tg9949 mice after inoculation of amyloid
fibrils (Legname et al. 2005). Increased resistance toward
denaturation is consistent with the formation of a larger
solvent-protected core during the transition from monomer
into amyloid conformation.
To distinguish different subtypes of PrPSc, limited diges-
tion with PK has been used widely, since it offers a rapid
and accurate assay of altered PrPSc conformation (McKinley
et al. 1983; Bessen and Marsh 1994; Safar et al. 1998;
Parchi et al. 1999; Hill et al. 2003; Notari et al. 2004). In our
previous study we failed to identify any PK-resistant poly-
peptides upon digestion of the amyloid fibrils using stan-
dard conditions for SDS-PAGE (Baskakov et al. 2002). In
the present study we found that PK-resistant polypeptides
can be detected by SDS-PAGE, but only when, in addition
to SDS-sample buffer, urea is added to the sample buffer to
a final concentration of 3 M. After PK digestion we ob-
served three major fragments having apparent molecular
masses of 12 kDa, 10 kDa, and 8 kDa (Fig. 2A, left panel).
As the PK to protein ratio increased, the size of PK-resistant
polypeptides was reduced. Thus, digestion at 1:2000 PK/
rPrP ratio produced primarily fragments with apparent mo-
lecular masses of 12 kDa and 10 kDa (lane 2), while at a
higher ratio (up to 1:20) the major PK-resistant fragments
were 10-kDa and 8-kDa peptide (lane 5). The PK/rPrP ratio
of 1:20 exceeds the PK-to-protein ratios that are normally
used in studies of PrPSc in brain homogenates (Caughey et
al. 1998; Safar et al. 1998). Moreover, our PK digestion
assay is free from nonprotein components of brain homog-
enate and from possible interference with PK activity. It is
noteworthy that when SDS-sample buffer was not supple-
mented with urea, we observed stalled bands on the top of
the stacking gel instead of 10-kDa and 8-kDa bands. Be-
cause treatment under highly denatured conditions, includ-
ing 3M urea, 2% SDS, and 95°C was necessary for analyses
of proteolytic products by SDS-PAGE, it is likely that the
PK-resistant core of the amyloid form remained assembled
in a highly stable, multimeric form.
To ensure that the PK-resistant fragments are not gener-
ated from cleavage of residual amounts of -rPrP 89-230
that may copresent in the preparation of the amyloid fibrils,
we treated -rPrP 89-230 with PK using identical diges-
tion conditions. At low concentrations of PK (PK/rPrP ra-
tios 1:2000 and 1:500), -rPrP 89-230 generated two
major fragments having apparent molecular masses of 14
kDa and 13 kDa (Fig. 2A, middle panel, lanes 2,3, re-
spectively). At higher concentrations of PK (PK/rPrP ratios
1:100 and 1:20), these fragments were completely digested
(lanes 4,5, respectively). The result of this control ex-
periment is consistent with previous studies that demon-
strated that PrPC undergoes proteolytic cleavage at amino
acid residues 110/111 to produce a C-terminal frag-
ment referred to as C1 (Chen et al. 1995). Taken together,
our studies shows that 8-kDa and 10-kDa fragments are
generated from the amyloid fibrils but not from -rPrP
89-230.
To identify the region that is resistant to PK digestion in
the amyloid conformation, we used Fabs P and R1, specific
to residues 96–105 and 225–230, respectively. The epitope
for Fab P was not present in any of the three major PK-
resistant products, while the epitope for Fab R1 was present
in all three fragments. Using liquid chromatography/mass
spectrometry (LC-MS) we showed that the three major PK-
resistant bands correspond to polypeptides spanning resi-
dues 138/141–230, 152/153–230, and 162–230 (Fig. 2B).
Both LC-MS and Western blot analyses demonstrate that
the C-terminal region of rPrP 89-230 remains PK-resistant
in the amyloid form, while the central region encompassing
residues 89–138 is fully susceptible to proteolysis (Fig. 3A).
Figure 1. GdnHCl-induced denaturation of the amyloid fibrils of rPrP
89-230. Amyloid fibrils were incubated for 30 min at 24°C () or 57°C (●)
in the presence of variable concentrations of GdnHCl. The GdnHCl con-
centration was then adjusted to 0.55 M, followed by a ThT-binding assay.
The experiments were conducted at least in duplicate. The lines represent
the results of the fitting to a two-state model (Santoro and Bolen 1988). The
increase in ThT fluorescence observed at low concentrations of denaturant
is due to GdnHCl-induced dissociation of coaggregated amyloid fibrils.
Bocharova et al.
1224 Protein Science, vol. 14
The 10-kDa and 8-kDa fragments produced at high PK/
rPrP ratio were different from C1 fragment generated upon
proteolytic digestion of PrPC (Chen et al. 1995), but remark-
ably similar to a minor population of PK-resistant fragments
of PrPSc identified recently in patients with spCJD (Fig.
3B;Zou et al. 2003). These fragments were found in 26 of
the 29 spCJD brains examined and accounted for up to 24%
of all PK-resistant PrP polypeptides in spCJD brains. Chen
and coauthors suggested that these short C-terminal frag-
ments were generated from a novel subpopulation of PrPSc
that adopts a conformation different from that of “classical”
PrPSc (Zou et al. 2003), which is known to produce a core
encompassing residues ∼90–230 upon PK digestion (for
clarity, the minor subpopulation of PrPSc produced in
spCJD will be referred to as novel PrPSc). Another group
reported that C-terminal PK-resistant fragments of 11–12
kDa were also associated with a certain type of iatrogenic
CJD; however, the exact positions of PK cleavage sites were
not determined (Satoh et al. 2003). Truncated, PK-resistant
C-terminal polypeptides of similar length were found in
brain homogenate from mice infected with mouse-passaged
hamster PrPSc strain 263K and in cell-free conversion as-
says under conditions that mimicked the hamster/mouse
species barrier (Lawson et al. 2004). The sites of PK cleav-
age were found to be between residues 130 and 157 as
localized by epitope mapping and mobility on a gel (Fig.
3C). Identification of novel C-terminal PK-resistant frag-
ments in patients with sporadic and iatrogenic CJD as well
as in mice suggested that their involvement in the patho-
genic process may be more common than had previously
been recognized (Satoh et al. 2003; Zou et al. 2003; Lawson
et al. 2004). On the basis of limited proteolysis, the amyloid
Figure 2. Limited PK digestion of the amyloid form of rPrP 89-230. (A) Amyloid fibrils or -rPrP 89-230 (0.2 mg/mL) were treated
with PK for 1 h at 37°C at the following PK:rPrP ratios (w/w): 1:2000 (lanes 2), 1:500 (lanes 3), 1:100 (lanes 4), 1:20 (lanes 5), no
PK (lanes 1) and analyzed by SDS-PAGE followed by silver staining (amyloid fibrils, left panel; -rPrP 89-230, middle panel) or by
Western blotting using Fabs R1 and P (right panel). MW markers, lane 6. A 14-kDa fragment detectible by Fab R1 appeared as a result
of partial degradation in the time-course of amyloid formation. (B) Online capillary HPLC-MS analysis of the amyloid form after
limited digestion with PK. Electrospray mass spectrum and deconvoluted mass spectrum of species (inset) showing partial resistance
to PK. Several PK-resistant species were identified by comparison of measured and theoretical masses, including polypeptides spanning
residues 138–230 (measured mass 11,395.56 Da; theoretical mass 11,395.56 Da), residues 141–230 (measured mass 10,997.32 Da;
theoretical mass 10,998.01 Da), residues 152–230 (measured mass 9,512.07 Da; theoretical mass 9,513.58 Da), residues 153–230
(measured mass 9,398.29 Da; theoretical mass 9,399.47 Da), and residues 162–230 (measured mass 8,182.63 Da; theoretical mass
8,184.07).
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form of rPrP 89-230 is similar to the novel rather than
classical subpopulations of PrPSc.
Multiple lines of evidence indicate that the central region
of PrP, encompassing residues 90–141, is important for
prion propagation (Tagliavini et al. 1993; Fischer et al.
1996; Peretz et al. 1997; Chabry et al. 1998). Puzzled by the
fact that this region is PK-labile in disease-producing amy-
loid fibrils and, therefore, expected to undergo rapid diges-
tion by endogenous proteases upon inoculation (Yadavalli
et al. 2004), we sought to determine whether the C-terminal
PK-resistant core maintains -sheet-rich structure and pos-
sesses self-propagating activity. To address these questions
we seeded the in vitro conversion reaction with the amyloid
form pretreated with PK. For this experiment we used ex-
perimental conditions at which spontaneous or nonseeded
formation of the amyloid fibrils occurred only after a pro-
longed lag phase of 60 h (Table 1). Seeding of the in vitro
reaction with fibrils not treated with PK substantially re-
duced the lag phase (Fig. 4A), and the data indicate a linear
dependence between the length of the lag phase and the
log[amount of seed] (Fig. 4B). Remarkably, the fibrils pre-
treated with PK for 1 h at 37°C showed substantial seeding
activity. As judged from the length of the lag phase, 2.5% of
amyloid fibrils pretreated with PK at 1:20 PK/rPrP ratio
exhibited apparent seeding activities that were equivalent to
the seeding activities that would be displayed by 0.75% of
intact fibrils (Fig. 4A,B; Table 1). At a PK:rPrP ratio of
1:20, only the 10-kDa and 8-kDa fragments, corresponding
to residues 152/153–230 and 162–230, respectively, were
detectable by Western blotting (Fig. 2A). This experiment
illustrates that the C-terminal PK-resistant core of the syn-
thetic prions preserves propagating activity in a cell-free
conversion assay.
Since treatment under highly denaturing conditions was
required for visualization of proteolytic products by SDS-
PAGE, it is likely that the PK-resistant core of the amyloid
fibrils remains assembled in a multimeric form. Therefore,
we sought to determine whether the C-terminal PK-resistant
core maintained fibrillar structure. Using electron micros-
copy we found that the amyloid form maintained fibrillar
structure upon cleavage of N-terminal region (Fig. 5A). PK-
treated fibrils had a higher tendency to coaggregate, prob-
ably due to an increase in accessibility of hydrophobic sur-
faces to the solvent upon PK digestion. Unfortunately, ag-
Figure 3. PK-resistant fragments. (A) PK-resistant core of the amyloid
fibrils of Mo rPrP 89-231; epitopes for Fabs P and R1 are highlighted
(present work). (B) PK-resistant core of the novel subpopulation of PrPSc
found in spCJD; sites of PK digestion were identified by N-terminal se-
quencing using Edman degradation (Zou et al. 2003). (C) PK-resistant core
of PrPSc generated in mice upon second passage of transmission of hamster
PrPSc strain 263 K as determined by Western blotting using an antibody
against the C terminus. Approximate sites of cleavage were identified by
epitope mapping of PK-resistant fragments of Mo PrP generated in the
cell-free conversion assay upon incubation with hamster PrPSc strain 263 K
(Lawson et al. 2004). (D) PK-resistant core of hamster (Ha) PrPSc gener-
ated in the presence of 2.5 M GdnHCl. The approximate location of PK
cleavage was found within residues 115–143 by epitope mapping, and is
represented by the light gray area (Kocisko et al. 1996). PK-resistant re-
gions are represented by the dark gray area, and partial PK-resistant regions
by the light gray area.
Table 1. Kinetic parameters for amyloid formation
Lag-phasea (hours)
Nonseeded 59.8 ± 0.1
1% seed 18.5 ± 0.5
0.2% seed 22.4 ± 0.9
0.04% seed 27.6 ± 0.1
2.5% seed + PKb 19.9 ± 0.7
a The lag-phases were determined by fitting the time-dependent changes in
the fluorescence of Thioflavin T vs. time of the reaction as described in
Materials and Methods.
b The amyloid fibrils used for seeding were pretreated with PK for 1 h at
37°C at PK:rPrP ratio of 1:20.
Figure 4. PK-resistant core of the amyloid form displays seeding activity.
(A) The kinetics of fibril formation for rPrP 89-230 (0.3 mg/mL; reaction
volume 0.15 mL) seeded with 0.04% (w/w) (brown triangles), 0.2% (or-
ange triangles), and 1% (yellow triangles) of preformed fibrils; with 2.5%
fibrils treated with PK (green triangles); and in nonseeded reaction (blue
triangles). Std. dev. for duplicate samples are represented by error bars.
The kinetics were monitored using the automated format as described in
Materials and Methods. (B) Dependence of the lag phase of fibrils forma-
tion on the amount of seed (circles); the solid line represents the result of
the fitting to a linear function. The apparent seeding activity in the reac-
tions seeded with 2.5% of fibrils pretreated with PK at PK/rPrP ratio of
1:20 (green square) was calculated using the linear dependence between
the length of the lag phase and Lg[amount of seed].
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gregation of PK-treated fibrils into large clumps hampered
quantitative analyses of the fibril width.
To test the extent to which PK digestion causes confor-
mational changes in fibril secondary structure, we employed
Fourier transform infrared spectroscopy (FTIR) using a Bio-
ATR cell, which allows FTIR spectra to be recorded from
aqueous solution. The FTIR spectrum acquired for -rPrP
89-230 was dominated by strong absorbance at 1651 cm−1
and 1645 cm−1 corresponding to -helices and random coil,
respectively (Fig. 5B). The FTIR spectrum of the amyloid
form was substantially different from that of the -mono-
mer. The second derivative analysis of the amyloid form
revealed a major band at 1622 cm−1, characteristic of
-sheet structures with strong intermolecular hydrogen
bonds, a smaller band at 1651 cm−1, indicative of -helices
and random coil, and a minor band at 1674 cm−1, charac-
teristic of -turns and loops (Fig. 5C). Upon treatment with
PK, the relative intensity of bands at 1651 cm−1 and 1674
cm−1 decreased, demonstrating loss of -helical structure
and -turns and loops, respectively. The relative intensity of
band at 1622 cm−1, a characteristic of -sheet structures, did
not change notably. On the other hand, the shift of the band
centered at 1622 cm−1 to 1626 cm−1 indicated that -struc-
tures with strong intermolecular hydrogen bonds acquired
some flexibility upon treatment with PK.
Since no cellular factors or templates were used for gen-
eration of the amyloid fibrils in vitro, the ability of rPrP
89-230 to adopt a conformation similar to that of novel
PrPSc reflects an intrinsic property of PrP that is indepen-
dent of the influence of cellular environments and/or cofac-
tors. While the N-terminal region of PrP, encompassing
residues 23–90, is not critical for transmission of prions, this
region is known to influence the conformation of protease-
resistant PrP isoforms (Wadsworth et al. 1999; Lawson et
al. 2004), and may substantially impact the conformational
diversity of fibrils generated in vitro. Therefore, we exam-
ined the conformation of the amyloid form generated from
murine full-length recombinant PrP (rPrP 23-230).
Conversion of rPrP 23-230 to the amyloid fibrils was
carried out using the same solvent conditions as those used
for the conversion of rPrP 89-230. FTIR analysis of rPrP
23-230 refolded into the amyloid form produced a spectrum
substantially different from that of the corresponding
-monomer (Fig. 6A). The spectrum of the amyloid form
showed a substantial decrease in intensity of the band at
1654 cm−1 corresponding to -helices and random coil, and
an increase in intensity of the band at 1617 cm−1, an indi-
cation of -structure with strong intermolecular hydrogen
bonds (Fig. 6B).
Analysis of PK-resistant fragments of the amyloid form
of rPrP 23-230 showed two distinct patterns of cleavage,
suggesting distinct subpopulations of conformers (Fig. 7A,
left panel). The major subpopulation of rPrP 23-230 pro-
duces PK-resistant fragments of 12 kDa, 10 kDa, and 8 kDa
similar to those identified from the PK digest of the amyloid
Figure 5. PK-resistant core of the amyloid form maintains -rich struc-
ture. (A) Electron micrographs of the amyloid fibrils of rPrP 89-230 with-
out PK treatment (left panel), and treated with PK at 37°C for 1 h at the PK
to rPrP ratio of 1:20 (right). Scale bar 0.5 m. (B) FTIR spectra of rPrP
89-230 in the -monomeric form (dashed line), the intact amyloid form
(solid line), and the amyloid form after treatment with PK (dotted line). (C)
Second derivatives of FTIR spectra. The line definitions are the same as for
panel B. Fibrils were incubated with PK for 1 h at 37°C at the PK:rPrP ratio
1:20.
Figure 6. In vitro conversion of rPrP 23-230 into the amyloid fibrils. (A)
FTIR spectra of rPrP 23-230 in the amyloid form (solid line) and in -
monomeric form (dashed line). (B) Second derivatives of FTIR spectra.
The line definitions are the same as for panel A.
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of rPrP 89-230. These fragments appear at low concentra-
tions of PK and show the same pattern of epitope presen-
tation as proteolytic fragments of the amyloid of rPrP 89-
230 (Fig. 7B, left, middle, and right panels). The minor
subfraction of rPrP 23-230, however, produces several
bands with molecular masses between 21 and 16 kDa. These
bands account for ∼5%–10% of all PK-resistant products, as
judged by SDS-PAGE (Fig. 7A, left panel). At PK:rPrP
ratios of 1:100 and 1:50, these bands are further digested to
generate a single PK-resistant product with molecular mass
of 16 kDa (Fig. 7A, left panel, lanes 6,7). The 16-kDa
fragment is consistently resistant to PK even upon incuba-
tion at the PK:rPrP ratio of 1:10 at 37°C for 1 h. This
polypeptide contains epitopes for Fab P (residues 96–105),
Fab D18 (residues 133–157), and Fab R1 (residues 225–
230) (Fig. 7B). As a control to confirm that 8-kDa, 10-kDa,
and 16-kDa PK-resistant fragments are generated from the
amyloid fibrils, we used -rPrP 23-230. At PK/rPrP ratios
of 1:100 and 1:50, -rPrP 23-230 was completely digested
with no PK-resistant fragments being detected (Fig. 7A, left
panel, lanes 6,7).
In parallel with limited PK digestion, two distinct sub-
populations of the amyloid fibrils were evident by use of
fluorescence and electron microscopy (Fig. 8). The majority
of fibrils display relatively weak Thioflavin T (ThT)-fluo-
rescence as seen by fluorescence microscopy (Fig. 8A). A
minor subpopulation of fibrils (5%–10%), however, exhib-
its substantially brighter emission, which remains stable
even after harsh PK treatment (Fig. 8A). This result is con-
sistent with the two conformers identified by limited diges-
tion in Figure 6. Two subpopulations of the fibrils were also
seen by electron microscopy, where the minor subpopula-
tion accounted for ∼5% of all fibrils (Fig. 8B).
The results of limited proteolysis show that, upon con-
version of rPrP 23-230 into the amyloid form, two subpopu-
lations of conformers are generated, which differ in their
Figure 7. Limited PK digestion of the amyloid form of rPrP 23-230 reveals two conformers. (A) SDS-PAGE followed by silver
staining represents the relative amount of PK-resistant fragments. Amyloid fibrils of rPrP 23-230 (left panel) or -rPrP 23-230 (0.2
mg/mL) (right) were treated with PK for 1 h at 37°C at the following PK:rPrP ratios (w/w): no PK (lanes 1), 1:10,000 (lanes 2), 1:5,000
(lanes 3), 1:1000 (lanes 4), 1:500 (lanes 5), 1:100 (lanes 6), and 1:50 (lanes 7). Apparent molecular masses of fragments are given in
kDa at the left. (B) Western blot of the PK-resistant fragments treated with three Fabs: P (left panel), D18 (middle), and R1 (right).
PK:rPrP ratios are the same as in panel A. The 9-kDa fragment containing epitope for Fab P appeared only at low PK:rPrP ratios (shown
by an arrow). This fragment, however, was fully digested at high concentrations of PK. (C) Two patterns of PK digestion. Epitopes
for Fab P are shown as light gray boxes, for D18 as dark gray boxes, and for R1 as black boxes; approximate locations of PK cleavage
sites are shown by small arrows.
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resistance to PK (Fig. 7C). The major subpopulation is more
sensitive to PK digestion and produces short C-terminal
PK-resistant fragments similar to those generated from
novel PrPSc. The minor subpopulation is characterized by
enhanced resistance to PK and possesses a C-terminal re-
sistant core identical to the PK-resistant fragments of clas-
sical PrPSc.
It is notable that conformers biochemically identical to
both novel and classical PrPSc can be generated in vitro
without any cellular cofactors or PrPSc-dependent templat-
ing. To date, the relationship between the novel and classi-
cal PrPSc remains speculative, but the results of proteolytic
digestion of PrPSc carried out under partially denaturing
conditions may provide an important link between the two
forms (Kocisko et al. 1996). Caughey and coauthors showed
that PK treatment of in vivo-derived hamster PrPSc in the
presence of 2.5 M GdnHCl resulted in digestion of the
N-terminal regions including residues 90–115 and, possibly,
90–143, while the C-terminal region remained intact (Fig.
3D;Kocisko et al. 1996). The C-terminal fragments of PrPSc
generated under partially denaturing conditions (Kocisko et
al. 1996) were similar to those produced from novel PrPSc
under native conditions (Zou et al. 2003). If the classical
and novel subpopulations of PrPSc indeed share a similar
substructure, the novel subpopulation may represent a meta-
bolic intermediate or byproduct of formation of classical
PrPSc. Remarkably, the third site targeted by PK in both the
amyloid fibrils and the novel subpopulation of PrPSc (resi-
due 162) coincides with the sequence YYR (residues 162–
164) (Paramithiotis et al. 2003). Epitope mapping using
antibodies raised to a peptide including this sequence has
shown that the epitope containing these residues is buried in
the native PrPC form, but becomes solvent-exposed upon
conversion to pathological PrPSc form.
Since the relative proportions of two amyloid conformers
generated in vitro are opposite to that of novel and classical
PrPSc in sporadic CJD, as yet unidentified cellular cofactors
may be required for efficient conversion of rPrP 23-230 into
a conformer similar to classical PrPSc. Such a cofactor may
promote assembly by counteracting the electrostatic repul-
sion of positively charged N-terminal regions that remain
exposed to the solvent upon conversion to the amyloid form.
Polyanions such as sulfated glycans or RNA may serve this
function. RNA and heparin sulfate have been shown to bind
to the N-terminal region of PrPC (Gonzalez-Iglesias et al.
2002; Warner et al. 2002; Gabus et al. 2004) and, further-
more, both RNA and sulfated glycans were found to stimu-
late cell-free conversion of PrPC into protease-resistant
PrPSc-like forms (Wong et al. 2001; Adler et al. 2003; De-
leault et al. 2003).
While the amyloid fibrils formed by rPrP 89-230 were
shown to cause a transmissible form of prion disease in
experimental animals, the incubation times observed upon
inoculation of the fibrils was longer than that exhibited by
most known PrPSc strains (Legname et al. 2004). It is im-
portant to note that natural strains of PrPSc evolved through
natural selection (Bartz et al. 2000). Only those strains that
show very fast rates of propagation and, correspondingly,
shorter incubation times are preferred by many laboratory
investigators. Moreover, most strains that are currently used
in laboratories were repassaged many times and therefore
adapt well to a particular host. One can speculate that the
shortening of the incubation times observed in the second
passages of synthetic prions may be attributed to the adap-
tation to the host, suggesting that an apparent transmission
barrier precludes efficient propagation of the amyloid fibrils
in the first passage. A transmission barrier is typically ob-
Figure 8. Two subpopulations of the amyloid fibrils of rPrP 23-230. (A)
Fluorescence microscopy of the amyloid fibrils (top panel). The emission
intensity (bottom panel) monitored across the image at the position shown
by the red dashed line. The fibrils of minor subpopulations display emis-
sion intensities four-–eightfold higher than that of fibrils of the major
subpopulation (scale bar 2 m). (B) Electron micrographs of negatively
stained fibrils (scale bar 0.5 m). The minor subpopulation displayed
much stronger propensity for staining with uranyl acetate and accounted
for ∼5%–10% of all fibrils.
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served when the sequence of PrPSc in the inoculum does not
match that of PrPC in the recipient animals (Pattison and
Jones 1968; Prusiner et al. 1990; Scott et al. 1993). Besides
the differences in the sequences of PrPs, different strains of
prion disease have different transmission barriers, presum-
ably as a result of different conformations of PrPSc (Barron
et al. 2003). Since the sequence of the amyloid fibrils was
identical to that of endogenously expressed PrPC (mouse
PrP 89-230), it is likely that the apparent transmission bar-
rier is due to the unique conformational properties of the
amyloid fibrils and, in particular, due to the proteolytic li-
ability of residues 90–138. In addition, the lack of glyco-
sylation in the amyloid fibrils may affect their conforma-
tional compatibility to PrPC and, therefore, also contribute
to the slow rate of propagation in the first passage and the
apparent transmission barrier. Remarkably, after primary
passage was accomplished, much shorter incubation times
in the second passage of the synthetic prions were observed
(Legname et al. 2004).
PK resistance of the central region and, in particular, the
3F4 epitope (residues 108–111) has historically been ex-
ploited to distinguish PrPSc from PrPC as a biochemical
marker for the presence of prion infection (McKinley et al.
1983; Oesch et al. 1985). Taken together, this study and that
by Legname and coauthors demonstrate that the amyloid
fibrils generated in vitro are capable of transmitting a prion
disease despite having a proteolytically labile region en-
compassing residues 90–138. These findings may explain
reports of prion infections in the absence of detectable PK-
resistant PrPSc (Lasmézas et al. 1997; Manuelidis et al.
1997; Barron et al. 2001; Tremblay et al. 2004). These
observations have serious implications for the development
of effective prion diagnostics.
Materials and methods
Expression and purification of recombinant PrPs
Mouse rPrP encompassing residues 89–230 was expressed and
purified as described previously (Baskakov 2004). The purified
proteins were confirmed to be single species with an intact disul-
fide bond by SDS-PAGE and electrospray mass spectrometry. De-
tailed protocols for purification and refolding of full-length mouse
rPrP 23-230 are described by Bocharova et al. (2005). Briefly, the
purification was achieved using NTA Fast Flow Sepharose resin
(Amersham Biosciences) precharged with Ni-ions, followed by
reverse-phase chromatography on C4 HPLC column (Vydac). rPrP
23-230 was confirmed to be 99.5+% pure with an intact disulfide
bond by SDS-PAGE with silver staining, electrospray mass spec-
trometry, and analytical size-exclusion chromatography.
In vitro conversion of PrPs into the amyloid fibrils
To form amyloid fibrils we used two different formats, manual and
automated. In the manual format, a stock solution of rPrP 89-230
or rPrP 23-230 (4 mg/mL) in 6 M GdnHCl was diluted to the final
protein concentration of 0.5 mg/mL and incubated at 37°C in 20
mM Na-acetate buffer, 1 M GdnHCl, 3 M urea, 150 mM NaCl (pH
5.0) with continuous shaking at 600 rpm using a Delfia plate
shaker (Wallac) in conical plastic tubes (Eppendorf) in a 0.6-mL
reaction volume. The kinetics of fibril formation were monitored
using a ThT-binding assay. Aliquots withdrawn during the time
course of incubation at 37°C were diluted into 5 mM Na-acetate
buffer (pH 5.5) to a final concentration of rPrP of 1 M, and then
ThT (Molecular Probes) was added to a final concentration of 10
M. Six emission spectra (from 460 to 520 nm) were recorded for
each sample in 0.4-cm rectangular cuvettes with excitation at 445
nm on a FluoroMax-3 fluorimeter (Jobin Yvon); both excitation
and emission slits were 4 nm. Spectra were averaged and the
fluorescence intensity at emission maximum (482 nm) was deter-
mined. In a typical experiment, we observed a 50-fold increase in
ThT-fluorescence per 1 M of rPrP 89-230 upon conversion into
the amyloid form.
To monitor the kinetics of amyloid formation in seeding experi-
ments, we used the automated format. The conversion in the au-
tomated format was carried out in PBS buffer, 1 M GdnHCl, 3 M
urea (pH 7.0) in a 0.15-mL volume in 96-well plates and in the
presence of ThT (10 M). Our preliminary studies using the
manual format demonstrated that the presence of 10 M ThT in
the reaction mixture does not interfere with the kinetics of amyloid
formation (data not shown). Three Teflon spheres (2.38-mm di-
ameter, McMaster-Carr) were placed into each well of a 96-well
plate; then the reaction mixture containing rPrP and ThT was
pipetted into wells, and the plates were covered by ELAS septum
sheets (Spike International), and incubated at 37°C upon continu-
ous shaking at 900 rpm in a Fluoroskan Ascent CF microplate
reader (ThermoLabsystems). The kinetics were monitored by bot-
tom reading of fluorescence intensity every 5 min using 444 nm
excitation and 485 nm emission filters.
The lag phase of amyloid formation was determined by fitting
the time-dependent changes in the fluorescence of ThT (F) over
time of the reaction (t) to the following equation:
F A + B / (1 + exp [k* (tm − t)]
where A is the base level of ThT fluorescence during the lag phase,
B is the difference between final level of ThT fluorescence at
plateau and the initial level during the lag phase, k is the rate
constant of fibril growth (h−1), and tm is the observed time at
midpoint of transition. The lag time (tl) of fibril formation was
calculated as: tl  tm−2/k. The apparent seeding activities in the
reactions seeded with 2.5% of fibrils pretreated with PK were
calculated using the linear dependence between the length of the
lag phase and Lg[amount of seed].
GdnHCl-induced denaturation of the amyloid fibrils
Mo rPrP 89-230 in amyloid conformation (7 L, 0.4 mg/mL) was
suspended in PBS (30 L, pH 7.2) containing GdnHCl (0.5–5.5
M). This solution was incubated for 30 min at a fixed temperature
(24°C or 57°C) and then diluted to 300 L with 8 M GdnHCl and
water to adjust the final concentration of GdnHCl to 0.55 M.
Fluorescence spectra were recorded in the presence of 10 M
thioflavin T (ThT) in 0.4-cm rectangular cuvettes, with excitation
at 445 nm, on a FluoroMax-3 fluorimeter (Jobin Yvon) at 24°C;
both excitation and emission slits were 4 nm. ThT bound to the
amyloid fibrils showed typical fluorescence spectra with the emis-
sion maximum at 482 nm. Background ThT fluorescence was
subtracted. C1/2 values were calculated according to the equation
C1/2  G/m, where G is apparent free energy of denaturation,
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and m represents the GdnHCl concentration dependence of the free
energy of denaturation. G and m values were calculated using
least-squares fit of the data to a two-state model using the linear
extrapolation method as described (Santoro and Bolen 1988).
Proteolysis with proteinase K
The amyloid forms or -helical forms of rPrP 89-230 (0.2 mg/mL)
and rPrP 23-230 (0.2 mg/mL) were dialyzed and treated with PK
at 37°C for 1 h in 100 mM Tris-HCl buffer (pH 7.2). Digestion was
stopped by quenching with PMSF (2 mM), followed by addition of
8 M urea, to a final concentration of 3 M, and 4X sample buffer to
a final concentration of 1X. Samples were heated at 95°C for 5 min
and analyzed by SDS-PAGE by use of precast 12% NuPage SDS
gels (Invitrogen). For Western blot experiments, proteins were
electroblotted onto Immobilon P PVDF membrane (Millipore),
incubated with anti-PrP Fabs (0.2 g/mL) followed by incubation
with goat anti-human IgG F(ab)2 fragment conjugated with HRP,
and detected using the ECL system (Pierce).
FTIR spectroscopy
FTIR spectra were measured by means of a Bruker Tensor 27
FTIR instrument (Bruker Optics) equipped with an MCT detector
cooled with liquid nitrogen. Both -rPrP and amyloid fibrils were
dialyzed against 10 mM Na-acetate buffer (pH 5.5), and 10 L of
each isoform (3 mg/mL of -rPrP, or 0.3 mg/mL of the amyloid
fibrils) was loaded into a BioATRcell II. Then, 128 scans at
2-cm−1 resolution were collected for each sample under constant
purging with nitrogen, corrected for water vapor; background
spectra of buffer were subtracted.
Mass spectrometry
Online capillary LC-MS analyses were performed at the Institute
for Animal Health proteomics facility as described (Gill et al.
2000). Briefly, samples were diluted to ∼1 pmol/L in 95:5
H2O:acetonitrile with 0.05% trifluoroacetic acid (TFA) (solvent
A), and ∼20 pmol was injected onto a preconcentration trap and
desalted by washing with the above solvent. Components were
separated on a home-packed capillary HPLC column (180-m i.d.,
5-m beads, 300 Å pore size, Jupiter C18, Phenomenex), previ-
ously equilibrated with solvent A, and were eluted by an increasing
gradient of solvent B, where solvent B was 5:95 H2O:acetonitrile
with 0.05% TFA. The flow rate was ∼1 L/min. The column
eluent was passed directly to a Quattro II tandem quadrupole mass
spectrometer (Waters UK) operated in positive ion mode. The
instrument was equipped with a continuous flow nanospray source
and acquired full scan mass spectra (m/z 300–2100) every 5 sec.
Negative staining and electron microscopy
Negative staining was performed on carbon-coated 100-mesh grids
coated with 0.01% of poly-L-lysine solution prior to staining. The
samples were adsorbed for 30 sec, washed with 0.1 M and 0.01 M
Na-acetate for 5 sec each, stained with freshly filtered 2% uranyl
acetate for 30 sec, dried, and then viewed in a Zeiss EM 10 CA
electron microscope.
Epifluorescence microscopy
Epifluorescence microscopy was carried out on an inverted micro-
scope (Nikon Eclipse TE2000-U) with the illumination system
X-Cite 120 (EXFO Photonics Solutions) connected through fiber
optics using a 1.3 aperture Plan Fluor 100x NA objective. The
emission was isolated from Rayleigh and Raman-shifted light by a
combination of filters: an excitation filter 485DF22, a beam splitter
505DRLPO2, and an emission filter 510LP (Omega Optical).
Digital images were acquired using a cooled 12-bit CoolSnap HQ
CCD camera (Photometrics). Fibrils were prestained with ThT (10
M) for 3 min prior to imaging.
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